Response to the Roche Clinical Trial for CLEMATIS

Categories: Blog, Ds Research, News
A response from LuMind Research Down Syndrome President and CEO Carolyn Cronin regarding the end of the Roche Clinical Trial for CLEMATIS. Hello friends, Like you we were disappointed to learn about the end of Roche Clinical Trial for CLEMATIS, the Phase II study investigating the efficacy and safety of basmisanil (RG1662) in adults and …

Read More

Federal Budget Updates Related to Down Syndrome Research

Categories: Blog, Ds / Alzheimer's Connection, News
Our Dr. Harpold stays closely connected to and works in the world of research, not only Down syndrome and Alzheimer’s disease, but also relevant research endeavors at a broad scale. Here’s his take on the Federal 2016 Omnibus Budget Bill. By Dr. Michael Harpold, LuMind RDS Chief Scientific Officer The just enacted Federal 2016 Omnibus Budget …

Read More

Clinton Campaign Announces Investment Plan for Alzheimer’s Disease

Categories: Blog, Ds / Alzheimer's Connection, News
LuMind Research Down Syndrome Foundation applauds the development and announcement by the Clinton presidential campaign of a formal plan for new investment to prevent, treat, and make an Alzheimer’s disease cure possible by 2025, which includes a commitment to reach the $2 billion annual funding level for NIH’s dementia research. You can read more details on Clinton’s announced plan …

Read More

Might Normalizing Brain Development Help in Down’s Syndrome?

Categories: Blog, Ds / Alzheimer's Connection, Ds Research

LuMind Research Down Syndrome Foundation’s Chief Scientific Officer Dr. Michael Harpold was referenced in a discussion from the Society for Neuroscience Annual Meeting. The article discusses if the cognitive impairments associated with Down syndrome could be prevented. Dr. Harpold was mentioned along with others from Tufts Medical in Boston, Univeristy of Bologna in Italy and Institute for Basic …

Read More